Eli Lilly and (NYSE:LLY) Now Covered by Credit Suisse Group

Credit Suisse Group started coverage on shares of Eli Lilly and (NYSE:LLYGet Rating) in a research note issued to investors on Thursday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $395.00 target price on the stock.

A number of other brokerages have also issued reports on LLY. Barclays increased their target price on shares of Eli Lilly and from $355.00 to $395.00 and gave the stock an overweight rating in a research report on Wednesday, November 2nd. UBS Group upgraded shares of Eli Lilly and from a neutral rating to a buy rating and increased their price target for the stock from $335.00 to $363.00 in a research report on Thursday, September 22nd. StockNews.com began coverage on shares of Eli Lilly and in a research report on Wednesday, October 12th. They set a buy rating on the stock. SVB Leerink increased their price target on shares of Eli Lilly and from $341.00 to $384.00 and gave the stock an outperform rating in a research report on Wednesday, November 2nd. Finally, Truist Financial increased their price target on shares of Eli Lilly and from $400.00 to $421.00 in a research report on Tuesday, November 15th. Three equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of Moderate Buy and a consensus price target of $355.89.

Eli Lilly and Stock Performance

Shares of NYSE:LLY opened at $361.67 on Thursday. The company’s 50 day moving average price is $335.81 and its two-hundred day moving average price is $320.01. Eli Lilly and has a 12-month low of $231.87 and a 12-month high of $369.80. The firm has a market cap of $343.65 billion, a PE ratio of 54.30, a PEG ratio of 2.28 and a beta of 0.36. The company has a quick ratio of 0.88, a current ratio of 1.13 and a debt-to-equity ratio of 1.39.

Eli Lilly and Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, December 9th. Shareholders of record on Tuesday, November 15th will be given a $0.98 dividend. The ex-dividend date of this dividend is Monday, November 14th. This represents a $3.92 dividend on an annualized basis and a yield of 1.08%. Eli Lilly and’s dividend payout ratio is currently 58.86%.

Insider Buying and Selling at Eli Lilly and

In other news, major shareholder Lilly Endowment Inc sold 101,631 shares of the firm’s stock in a transaction on Wednesday, September 28th. The shares were sold at an average price of $335.07, for a total transaction of $34,053,499.17. Following the completion of the transaction, the insider now owns 103,773,810 shares of the company’s stock, valued at $34,771,490,516.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, major shareholder Lilly Endowment Inc sold 101,631 shares of the firm’s stock in a transaction on Wednesday, September 28th. The shares were sold at an average price of $335.07, for a total transaction of $34,053,499.17. Following the completion of the transaction, the insider now owns 103,773,810 shares of the company’s stock, valued at $34,771,490,516.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Alonzo Weems sold 656 shares of the firm’s stock in a transaction on Monday, October 10th. The shares were sold at an average price of $326.23, for a total transaction of $214,006.88. Following the transaction, the executive vice president now directly owns 6,950 shares of the company’s stock, valued at approximately $2,267,298.50. The disclosure for this sale can be found here. Insiders have sold 571,297 shares of company stock worth $193,929,777 over the last quarter. Corporate insiders own 0.12% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and

Hedge funds have recently bought and sold shares of the company. Benjamin Edwards Inc. raised its holdings in Eli Lilly and by 0.7% in the third quarter. Benjamin Edwards Inc. now owns 3,836 shares of the company’s stock worth $1,240,000 after purchasing an additional 28 shares in the last quarter. Moloney Securities Asset Management LLC raised its holdings in Eli Lilly and by 0.6% in the third quarter. Moloney Securities Asset Management LLC now owns 5,000 shares of the company’s stock worth $1,617,000 after purchasing an additional 28 shares in the last quarter. Auxano Advisors LLC raised its holdings in Eli Lilly and by 2.1% in the third quarter. Auxano Advisors LLC now owns 1,385 shares of the company’s stock worth $448,000 after purchasing an additional 28 shares in the last quarter. Nations Financial Group Inc. IA ADV raised its holdings in Eli Lilly and by 1.7% in the third quarter. Nations Financial Group Inc. IA ADV now owns 1,774 shares of the company’s stock worth $574,000 after purchasing an additional 29 shares in the last quarter. Finally, Avidian Wealth Solutions LLC raised its holdings in Eli Lilly and by 0.4% in the third quarter. Avidian Wealth Solutions LLC now owns 7,354 shares of the company’s stock worth $2,378,000 after purchasing an additional 30 shares in the last quarter. Institutional investors own 82.45% of the company’s stock.

About Eli Lilly and

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Further Reading

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.